心臓　55/9　2023年9月号

出版社： 日本医学出版
発行日： 2023-09-15
分野： 臨床医学：内科  >  雑誌
ISSN： 05864488
雑誌名：
電子書籍版： 2023-09-15
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

目次

  • Open HEART
    　心臓血管外科医を育てる

    HEART’s Selection
    　肥大型心筋症のリモデリングとミオシン阻害薬の可能性
    　肥大型心筋症のリモデリングとミオシン阻害薬の可能性
    　　1．HCMの概要
    　　2．HCMの現行治療と左室リモデリングへの効果
    　　3．ミオシン阻害薬の作用メカニズム
    　　4．ミオシン阻害薬の臨床試験

    [連載]HEART's　Column
    Authorが語る日本発のクリニカル・エビデンス：論文の解説と発表後の展望
    　Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation
    　超高齢心房細動患者に対する低用量エドキサバン（ELDERCARE-AF試験）

    [連載]HEART’s Up To Date
    循環器医が知っておくべき最新のエビデンス

    HEART’s Original
    [臨床研究]
    奈良県における新型コロナウイルス感染症(COVID-19)がST上昇型急性心筋梗塞患者の
    　冠動脈再灌流時間に与えた影響

    [Editorial Comment]
    名古路論文に対するEditorial　Comment

    [Editorial Comment]
    名古路論文に対するEditorial　Comment

    [症例]
    エルゴメーター運動負荷ABPIで下肢虚血を証明できた急性B型大動脈解離の１例

    [症例]
    多量血栓による急性心筋梗塞を発症した原発性副甲状腺機能亢進症の1例

    [Editorial Comment]
    神人論文に対するEditorial　Comment

    [症例]
    食道通過障害を伴う弓部囊状大動脈瘤に対する全弓部置換術の1例

    [症例]
    先天性プロテインS欠損症による繰り返す深部静脈血栓症に対してエドキサバンが有効であった症例

    HEART’s Special
    潜因性脳梗塞に対する経皮的卵円孔開存閉鎖術の手引き 第2版
    日本脳卒中学会、日本循環器学会、日本心血管インターベンション治療学会

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【HEART' s Selection】

P.878 掲載の参考文献
1) Marian AJ, Braunwald E : Hypertrophic Cardiomyopathy : Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res 2017 ; 121 : 749-770
 
2) Maron BJ, Maron MS, Semsarian C : Genetics of hypertrophic cardiomyopathy after 20 years : clinical perspectives. J Am Coll Cardiol 2012 ; 60 : 705-715
 
3) Redwood CS, Moolman-Smook JC, Watkins H : Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 1999 ; 44 : 20-36
 
4) Coppini R, Ho CY, Ashley E, et al : Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. J Am Coll Cardiol 2014 ; 64 : 2589-2600
 
5) Olivotto I, Oreziak A, Barriales-Villa R, et al : Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020 ; 396 : 759-769
 
6) Ho CY, Mealiffe ME, Bach RG, et al : Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2020 ; 75 : 2649-2660
 
7) Ho CY, Day SM, Ashley EA, et al : Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy : Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 2018 ; 138 : 1387-1398
 
8) Hebl VB, Miranda WR, Ong KC, et al : The Natural History of Nonobstructive Hypertrophic Cardiomyopathy. Mayo Clin Proc 2016 ; 91 : 279-287
 
9) Marstrand P, Han L, Day SM, et al : Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction : Insights From the SHaRe Registry. Circulation 2020 ; 141 : 1371-1383
 
10) Neubauer S, Kolm P, Ho CY, et al : Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. J Am Coll Cardiol 2019 ; 74 : 2333-2345
 
11) Harper AR, Goel A, Grace C, et al : Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet 2021 ; 53 : 135-142
 
12) Kaltenecker E, Schleihauf J, Meierhofer C, et al : Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy. Cardiovasc Diagn Ther 2019 ; 9 (Suppl 2) : S299-s309
 
13) Pandit B, Sarkozy A, Pennacchio LA, et al : Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007 ; 39 : 1007-1012
 
14) Wu X, Simpson J, Hong JH, et al : MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1 (L613V) mutation. J Clin Invest 2011 ; 121 : 1009-1025
 
15) Lioncino M, Monda E, Verrillo F, et al : Hypertrophic Cardiomyopathy in RASopathies : Diagnosis, Clinical Characteristics, Prognostic Implications, and Management. Heart Fail Clin 2022 ; 18 : 19-29
 
16) Crilley JG, Boehm EA, Blair E, et al : Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003 ; 41 : 1776-1782
 
17) Yotti R, Seidman CE, Seidman JG : Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies. Annu Rev Genomics Hum Genet 2019 ; 20 : 129-153
 
18) Ho CY, Lopez B, Coelho-Filho OR, et al : Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010 ; 363 : 552-563
 
19) Shimada YJ, Hasegawa K, Kochav SM, et al : Application of Proteomics Profiling for Biomarker Discovery in Hypertrophic Cardiomyopathy. J Cardiovasc Transl Res 2019 ; 12 : 569-579
 
20) Shimada YJ, Raita Y, Liang LW, et al : Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy. Circ Heart Fail 2021 ; 14 : e007849
PubMed
21) Liang LW, Raita Y, Hasegawa K, et al : Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy. Heart 2022 ; 108 : 1807-1814
 
22) Liang LW, Hasegawa K, Maurer MS, et al : Comprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways. Circ Heart Fail 2023 ; 16 : e010010
PubMed
23) Musumeci B, Tini G, Russo D, et al : Left Ventricular Remodeling in Hypertrophic Cardiomyopathy : An Overview of Current Knowledge. J Clin Med 2021 ; 10 : 1547
PubMed
24) Olivotto I, Cecchi F, Poggesi C, Yacoub MH : Patterns of disease progression in hypertrophic cardiomyopathy : an individualized approach to clinical staging. Circ Heart Fail 2012 ; 5 : 535-546
 
25) Spirito P, Maron BJ : Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1987 ; 9 : 1013-1017
 
26) Harris KM, Spirito P, Maron MS, et al : Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006 ; 114 : 216-225
 
27) Palandri C, Santini L, Argiro A, et al : Pharmacological Management of Hypertrophic Cardiomyopathy : From Bench to Bedside. Drugs 2022 ; 82 : 889-912
 
28) Sen-Chowdhry S, Jacoby D, Moon JC, McKenna WJ : Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol 2016 ; 13 : 651-675
 
29) Dybro AM, Rasmussen TB, Nielsen RR, et al : Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2021 ; 78 : 2505-2517
 
30) Hamada M, Shigematsu Y, Ikeda S, et al : Impact of cibenzoline treatment on left ventricular remodelling and prognosis in hypertrophic obstructive cardiomyopathy. ESC Heart Fail 2021 ; 8 : 4832-4842
 
31) Sherrid MV, Barac I, McKenna WJ, et al : Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005 ; 45 : 1251-1258
 
32) Coppini R, Ferrantini C, Pioner JM, et al : Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy : A Translational Study. JACC Basic Transl Sci 2019 ; 4 : 795-813
 
33) Coats CJ, Pavlou M, Watkinson OT, et al : Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy : A Randomized Clinical Trial. JAMA Cardiol 2019 ; 4 : 230-235
 
34) Olivotto I, Camici PG, Merlini PA, et al : Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy : The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study. Circ Heart Fail 2018 ; 11 : e004124
PubMed
35) Maron MS, Chan RH, Kapur NK, et al : Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med 2018 ; 131 : 837-841
 
36) Khachfe HH, Salhab HA, Fares MY, Khachfe HM : Current State of Hypertrophic Cardiomyopathy Clinical Trials. Glob Heart 2019 ; 14 : 317-325
 
37) Teekakirikul P, Eminaga S, Toka O, et al : Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest 2010 ; 120 : 3520-3529
 
38) Shimada YJ, Passeri JJ, Baggish AL, et al : Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail 2013 ; 1 : 480-487
 
39) Axelsson A, Iversen K, Vejlstrup N, et al : Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy : the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2015 ; 3 : 123-131
 
40) Ho CY, Day SM, Axelsson A, et al : Valsartan in early-stage hypertrophic cardiomyopathy : a randomized phase 2 trial. Nat Med 2021 ; 27 : 1818-1824
 
41) Ommen SR, Mital S, Burke MA, et al : 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020 ; 142 : e558-e631
 
42) Kitaoka H, Tsutsui H, Kubo T, et al : JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies. Circ J 2021 ; 85 : 1590-1689
 
43) Maekawa Y, Akita K, Tsuruta H, et al : Significant reduction of left atrial volume concomitant with clinical improvement after percutaneous transluminal septal myocardial ablation for drug-refractory hypertrophic obstructive cardiomyopathy, and its precise detection with multidetector CT. Open Heart 2016 ; 3 : e000359
PubMed
44) Akita K, Kaneko Y, Sato R, et al : 4D Computed Tomography Visualization of Effective Septal Reduction After Alcohol Septal Ablation for Fatal Hypertrophic Obstructive Cardiomyopathy. Circ J 2022 ; 86 : 725
PubMed
45) Deb SJ, Schaff HV, Dearani JA, et al : Septal myectomy results in regression of left ventricular hypertrophy in patients with hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 2004 ; 78 : 2118-2122
 
46) Moravsky G, Bruchal-Garbicz B, Jamorski M, et al : Myocardial mechanical remodeling after septal myectomy for severe obstructive hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2013 ; 26 : 893-900
 
47) Parbhudayal RY, Guclu A, Zweerink A, et al : Myocardial adaptation after surgical therapy differs for aortic valve stenosis and hypertrophic obstructive cardiomyopathy. Int J Cardiovasc Imaging 2019 ; 35 : 1089-1100
 
48) Rowin EJ, Hausvater A, Link MS, et al : Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation 2017 ; 136 : 2420-2436
 
49) Olivotto I, Cecchi F, Casey SA, et al : Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001 ; 104 : 2517-2524
 
50) Ommen SR, Mital S, Burke MA, et al : 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy : Executive Summary : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2020 ; 76 : 3022-3055
 
51) Providencia R, Elliott P, Patel K, et al : Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy : a systematic review and meta-analysis. Heart 2016 ; 102 : 1533-1543
 
52) Maron BJ, Doerer JJ, Haas TS, et al : Sudden deaths in young competitive athletes : analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009 ; 119 : 1085-1092
 
53) O'Mahony C, Jichi F, Pavlou M, et al : A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014 ; 35 : 2010-2020
 
54) Chan RH, Maron BJ, Olivotto I, et al : Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014 ; 130 : 484-495
 
55) Rowin EJ, Maron BJ, Carrick RT, et al : Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2020 ; 75 : 3033-3043
 
56) Pasqualucci D, Fornaro A, Castelli G, et al : Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy. Circ Heart Fail 2015 ; 8 : 1014-1021
 
57) Rowin EJ, Maron BJ, Abt P, et al : Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. Am J Cardiol 2018 ; 121 : 986-996
 
58) Topilsky Y, Pereira NL, Shah DK, et al : Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail 2011 ; 4 : 266-275
 
59) Zuniga Cisneros J, Stehlik J, Selzman CH, et al : Outcomes in Patients With Hypertrophic Cardiomyopathy Awaiting Heart Transplantation. Circ Heart Fail 2018 ; 11 : e004378
PubMed
60) Houdusse A, Sweeney HL : How Myosin Generates Force on Actin Filaments. Trends Biochem Sci 2016 ; 41 : 989-997
 
61) Tsukamoto O : Direct Sarcomere Modulators Are Promising New Treatments for Cardiomyopathies. Int J Mol Sci 2019 ; 21 : 226
PubMed
62) Spudich JA, Aksel T, Bartholomew SR, et al : Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human β-cardiac myosin. J Exp Biol 2016 ; 219 : 161-167
 
63) Spudich JA : Hypertrophic and dilated cardiomyopathy : four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys J 2014 ; 106 : 1236-1249
 
64) Sommese RF, Sung J, Nag S, et al : Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function. Proc Natl Acad Sci U S A 2013 ; 110 : 12607-12612
 
65) Adhikari AS, Kooiker KB, Sarkar SS, et al : Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin. Cell Rep 2016 ; 17 : 2857-2864
 
66) McNamara JW, Li A, Dos Remedios CG, Cooke R : The role of super-relaxed myosin in skeletal and cardiac muscle. Biophys Rev 2015 ; 7 : 5-14
 
67) Alamo L, Koubassova N, Pinto A, et al : Lessons from a tarantula : new insights into muscle thick filament and myosin interacting-heads motif structure and function. Biophys Rev 2017 ; 9 : 461-480
 
68) Alamo L, Ware JS, Pinto A, et al : Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes. Elife 2017 ; 6 : e24634
PubMed
69) Green EM, Wakimoto H, Anderson RL, et al : A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 2016 ; 351 : 617-621
 
70) Kawas RF, Anderson RL, Ingle SRB, et al : A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem 2017 ; 292 : 16571-16577
 
71) Palmer BM, Wang Y, Teekakirikul P, et al : Myofilament mechanical performance is enhanced by R403Q myosin in mouse myocardium independent of sex. Am J Physiol Heart Circ Physiol 2008 ; 294 : H1939-1947
 
72) Anderson RL, Trivedi DV, Sarkar SS, et al : Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci U S A 2018 ; 115 : E8143-e8152
 
73) Rohde JA, Roopnarine O, Thomas DD, Muretta JM : Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. Proc Natl Acad Sci U S A 2018 ; 115 : E7486-E7494
 
74) Sewanan LR, Shen S, Campbell SG : Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue. Am J Physiol Heart Circ Physiol 2021 ; 320 : H1112-H1123
 
75) Stern JA, Markova S, Ueda Y, et al : A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy. PLoS One 2016 ; 11 : e0168407
PubMed
76) Heitner SB, Jacoby D, Lester SJ, et al : Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy : A Clinical Trial. Ann Intern Med 2019 ; 170 : 741-748
 
77) Olivotto I, Oreziak A, Barriales-Villa R, et al : Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020 ; 396 : 759-769
 
78) Desai MY, Owens A, Geske JB, et al : Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. J Am Coll Cardiol 2022 ; 80 : 95-108
 
79) Desai MY, Owens AT, Geske JB, et al : Dose-Blinded Myosin Inhibition in Patients with Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy : Outcomes Through 32-Weeks. Circulation 2023 ; 147 : 850-863
 
80) U.S. Food and Drug Administration : FDA approves new drug to improve heart function in adults with rare heart condition. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition (cited 2023 Jul 10)
 
81) Drugs.com : Mavacamten Dosage Guide + Max Dose, Adjustments -. https://www.drugs.com/dosage/mavacamten.html (cited 2023 Jul 10)
 
82) Chuang C, Collibee S, Ashcraft L, et al : Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J Med Chem 2021 ; 64 : 14142-14152
 
83) Maron MS, Masri A, Choudhury L, et al : Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2023 ; 81 : 34-45
 
84) Hegde SM, Lester SJ, Solomon SD, et al : Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2021 ; 78 : 2518-2532
 
85) Saberi S, Cardim N, Yamani M, et al : Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy : EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis. Circulation 2021 ; 143 : 606-608
 

【連載】

P.887 掲載の参考文献
1) Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, Eshima K, Tanizawa K, Fukuzawa M, Hayashi T, Akishita M, Lip GYH, Yamashita T : Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020 ; 383 : 1735-1745
 
2) 日本循環器学会/日本不整脈心電学会 : 2020年改訂版 不整脈薬物治療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf (cited 2023 Jul 27)
 
3) Okumura K, Tomita H, Nakai M, et al : Risk factors associated with ischemic stroke in Japanese patients with nonvalvular atrial fibrillation. JAMA Network Open 2020 ; 3 : e202881
PubMed
4) Kato ET, Goto S, Giugliano RP : Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev 2019 ; 49 : 115-124
 
5) Koretsune Y, Yamashita T, Akao M, et al : Baseline demographics and clinical characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry. Circ J 2019 ; 83 : 1538-1545
 
6) Giugliano RP, Ruff CT, Braunwald E, et al : Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013 ; 369 : 2093-2104
 
7) Ruff CT, Giugliano RP, Braunwald E, et al : Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes : an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015 ; 385 : 2288-2295
 
8) Rich MW, Chyun DA, Skolnick AH, et al : Knowledge gaps in cardiovascular care of the older adult population. J Am Coll Cardiol 2016 ; 67 : 2419-2440
 
9) Koretsune Y, Yamashita T, Kimura T, et al : Short term safety and plasma concentrations of edoxaban in Japanese patients with nonvalvular atrial fibrillation and severe renal impairment. Circ J 2015 ; 79 : 1486-1495
 
10) Hart RG, Benavente O, McBride R, et al : Antithrombotic therapy to prevent stroke in patients with atrial fibrillation : a meta-analysis. Ann Intern Med 1999 ; 131 : 492-501
 

【HEART' s Original】

P.895 掲載の参考文献
1) NHK : 奈良県の新型コロナデータ. https://www3.nhk.or.jp/news/special/coronavirus/data/pref/nara.html (cited 2022 Mar 11)
 
2) 日本循環器学会 : 急性冠症候群ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/11/JCS2018_kimura.pdf (cited 2022 Jun 18)
 
3) Cataldo P, Verdugo FJ, Bonta C, et al : Consequences of COVID-19 pandemic on myocardial infarction reperfusion therapy and prognosis. Rev Med Chil 2021 ; 149 : 672-681
 
4) Matsubara Y, Izumikawa T, Washimi S, et al : Impact of the SARS-CoV-2 Pandemic on Primary Percutaneous Coronary Intervention for Patients with ST-Elevation Myocardial Infarction. Int Heart J 2021 ; 62 : 1230-1234
 
5) Mahase E : Covid-19 : WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. BMJ 2020 ; 368 : m1036
PubMed
6) 日本心血管インターベンション治療学会 : 新型コロナウイルスパンデミック下の感染対策についての提言. https://www.cvit.jp/files/covid-19.pdf (cited 2023 Feb 13)
 
7) Fu XY, Shen XF, Cheng YR, et al : Effect of COVID-19 outbreak on the treatment of patients time with acute ST-segment elevation myocardial infarction. Am J Emerg Med 2021 ; 44 : 192-197
 
8) De Luca G, Verdoia M, Cercek M, et al : Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. J Am Coll Cardiol 2020 ; 76 : 2321-2330
 
9) Cinier G, Hayiroglu M, Pay L, et al : Effect of the COVID-19 pandemic on access to primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Turk Kardiyol Dern Ars 2020 ; 48 : 640-645
 
10) Kwok CS, Gale CP, Kinnaird T, et al : Impact of COVID-19 on percutaneous coronary intervention for ST-elevation myocardial infarction. Heart 2020 ; 106 : 1805-1811
 
11) Watanabe Y, Miyachi H, Mozawa K, et al : Impact of the COVID-19 Pandemic on ST-elevation Myocardial Infarction from a Single-center Experience in Tokyo. Intern Med 2021 ; 60 : 3693-3700
 
12) Kobayashi S, Sakakura K, Jinnouchi H, et al : Comparison of door to balloon time and in-hospital outcomes in patients with ST-elevation myocardial infarction between before versus after COVID-19 pandemic. Cardiovasc Interv Ther 2022 ; 37 : 641-650
 
13) Zahler D, Rozenfeld KL, Pasternak Y, et al : Relation of Pain-to-Balloon Time and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Am J Crdiol 2022 ; 163 : 38-42
 
P.898 掲載の参考文献
1) Gersh BJ, Stone GW, White HD, et al : Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction : is the slope of the curve the shape of the future? JAMA 2005 ; 293 : 979-986
 
2) Shiomi H, Nakagawa Y, Morimoto T, et al : Association of onset to balloon and door to balloon time with long term clinical outcome in patients with ST elevation acute myocardial infarction having primary percutaneous coronary intervention : observational study. BMJ 2012 ; 344 : e3257
PubMed
P.899 掲載の参考文献
1) 日本心血管インターベンション治療学会 : 「新型コロナウイルス感染拡大下の心臓カテーテル検査及び治療に関する提言」2020年4月13日 第1報. https://www.cvit.jp/files/news/2020/0413.pdf (cited 2023 May 30)
 
P.905 掲載の参考文献
1) Reutersberg B, Trenner M, Haller B, et al : The incidence of delayed complications in acute type B aortic dissections in underestimated. J Vasc Surg 2018 ; 68 : 356-363
 
2) Hagan PG, Nienaber CA, Isselbacher EM, et al : The international registry of acute aortic dissection (IRAD) : new insights into an old disease. JAMA 2000 ; 283 : 897-903
 
3) Nienaber CA, Eagle KA : Aortic dissection : new frontiers in diagnosis and management : part II : therapeutic management and follow-up. Circulation 2003 ; 108 : 772-778
 
4) Hughes GC, Andersen ND, McCann RL : Management of acute type B aortic dissection. J Thorac Cardiovasc Surg 2013 ; 145 : S202-207
 
5) Song JM, Kim SD, Kim JH, et al : Long-term predictors of descending aorta aneurysmal change in patients with aortic dissection. J Am Coll Cardiol 2007 ; 50 : 799-804
 
6) Williams DM, Lee DY, Hamilton BH, et al : The dissected aorta : percutaneous treatment of ischemic complications -priciples and results. J Vasc Interv Radiol 1997 ; 8 : 605-625
 
7) 日本循環器学会/日本心臓血管外科学会/日本胸部外科学会/日本血管外科学会 : 2020年改訂版 大動脈瘤・大動脈解離診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/07/JCS2020_Ogino.pdf (cited 2023 Apr)
 
8) Arata K, Imagama I, Shigehisa Y, et al : Aortic fenestration for type B chronic aortic dissection complicated with lower limb malperfusion induced by walking exercise. Ann Vasc Dis 2015 ; 8 : 29-32
 
9) Patel HJ, Williams DM, Meekov M, et al : Long-term results of percutaneous management of malperfusion in acute type B aortic dissection : implications for thoracic aortic endovascular repair. J Thorac Cardiovasc Surg 2009 ; 138 : 300-308
 
10) Dake MD, Kato N, Mitchell RS, et al : Endovascular stent-graft placement for the treatment of acute aortic dissection. N Engl J Med 1999 ; 340 : 1546-1552
 
11) 加藤憲幸, 茅野修二, 橋本考司, 東川貴俊 : 急性B型大動脈解離に対するステントグラフト治療. 心臓 2013 ; 45 : 1096-1100
 
12) van Bogerijen GH, Williams DM, Patel HJ : TEVAR for complicated acute type B dissection with malperfusion. Ann Cardiothorac Surg 2014 ; 3 : 423-427
 
13) 光部啓治郎, 赤坂伸之, 内田恒, ほか : ステントグラフトおよび上腸間膜動脈逆行性ステント挿入にて救命し得た, 急性B 型大動脈解離による腸管虚血の1例. 脈管学 2015 ; 55 : 147-151
 
14) Charlton-Ouw KM, Sandhu HK, Leake SS, et al : Need for limb revascularization in patients with acute aortic dissection is associated with mesenteric ischemia. Ann Vasc Surg 2016 ; 36 : 112-120
 
15) Nakahira A, Ogino H, Mtsuda H, et al : Postural change causing leg malperfusion resulting from expansion of a patent false lumen in type B aortic dissection. J Thorac Cardiovasc Surg 2007 ; 134 : 1046-1047
 
16) Yoshimuta T, Tsuneto A, Okajima T, et al : Doppler ultrasound diagnosis of transient leg malperfusion caused by dynamic obstruction in a patient with chronic aortic dissection. Echocardiography 2019 ; 36 : 189-191
 
17) Takahashi B, Kamohara K : A useful exercise test for detecting leg malperfusion due to aortic dissection. J Cardiol Cases 2022 ; 25 : 247-249
 
18) 北條禎久, 三好麻衣子, 井村真里 : 運動負荷後片側下肢虚血を呈したB型大動脈解離症例に対するステントグラフト (TEVAR) による1治験例. 心臓 2014 ; 46 : 1594-1599
 
P.912 掲載の参考文献
1) Obara T, Fujimoto Y : Diagnosis and Treatment of Patients with Parathyroid Carcinoma : An Update and Review. World J Surg 1991 ; 15 : 738-744
 
2) Fitzpatrick LA, Bilezikian JP : Acute Primary Hyperparathyroidism. Am J Med 1987 ; 82 : 275-282
 
3) Andersson P, Rydberg E, Willenheimer R : Primary hyperparathyroidism and heart disease--a review. Eur Heart J 2004 ; 25 : 1776-1787
 
4) Yao L, Folsom AR, Pankow JS, et al : Parathyroid hormone and the risk of incident hypertension : the Atherosclerosis Risk in Communities study. J Hypertens 2016 ; 34 : 196-203
 
5) Vlachakis ND, Frederics R, Valasquez M, et al : Sympathetic system function and vascular reactivity in hypercalcemic patients. Hypertension 1982 ; 4 : 452-458
 
6) Kiernan TJ, O'Flynn AM, McDermott JH, Kearney P : Primary hyperparathyroidism and the cardiovascular system. Int J Cardiol 2006 ; 113 : E89-92
 
7) Brown J, de Boer IH, Robinson-Cohen C, et al : Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors : the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab 2015 ; 100 : 490-499
 
8) Osto E, Fallo F, Pelizzo MR, et al : Coronary Microvascular Dysfunction Induced by Primary Hyperparathyroidism is Restored After Parathyroidectomy. Circulation 2012 ; 126 : 1031-1039
 
9) Vestergaard P, Mollerup CL, Frokjaer VG, et al : Cardiovascular Events before and after Surgery for Primary Hyperparathyroidism. World J Surg 2003 ; 27 : 216-222
 
P.913 掲載の参考文献
1) Andersson P, Rydberg E, Willenheimer R : Primary hyperparathyroidism and heart disease--a review : a review. Eur Heart J 2004 ; 25 : 1776-1787
 
2) Hagstrom E, Hellman P, Larsson TE, et al : Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009 ; 119 : 2765-2771
 
3) Rashid G, Bernheim J, Green J, Benchetrit S : Parathyroid hormone stimulates the endothelial nitric oxide synthase through protein kinase A and C pathways. Nephrol Dial Transplant 2007 ; 22 : 2831-2837
 
4) Osto E, Fallo F, Pelizzo MR, et al : Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation 2012 ; 126 : 1031-1039
 
P.920 掲載の参考文献
1) Ogino H, Ando M, Sasaki H, Minatoya K : Total arch replacement using a stepwise distal anastomosis for arch aneurysms with distal extension. Eur J Cardiothorac Surg 2006 ; 29 : 255-257
 
2) Grimaldi S, Milito P, Lovece A, et al : Dysphagia aortica. Eur Surg 2022 ; 54 : 228-239
 
3) 青木洋介, 加藤収, 中西洋一ほか : 大動脈瘤による圧迫が成因と考えられたTracheopathia osteochondroplasticaの1例. 気管支学 1989 ; 11 : 604-607
 
4) Petrov I, Nedevska M, Chilingirova N, et al : Endovascular repair of dissecting thoracic aortic aneurysm in a patient with Turner syndrome. J Endovasc Ther 2006 ; 13 : 693-696
 
5) Ebihara T, Yamasaki M, Kubo H, Yamaya M : Dysphagia in a patient with rapidly enlarged thoracic aortic aneurysm. J Am Geriatr Soc 2006 ; 54 : 1294
 
6) Siddiqui J, Hughes F : Dysphagia due to thoracic aortic aneurysm, relieved by thoracic endovascular aneurysm repair : a case report and review of the literature. BMJ Case Rep 2011 ; bcr0920114793
PubMed
7) Godar M, Yuan Q, Zhang P, et al : Multiple thoracic aortic aneurysms and dysphagia aortica. Eur Heart J Cardiovasc Imaging 2013 ; 14 : 1026
 
8) Kyaw WA, Lim CY, Khalil MAM, et al : A fatal case of Ortner's syndrome and dysphagia aortica secondary to rapidly expanding mycotic thoracic aortic aneurysm in a chronic kidney disease patient. SAGE Open Med Case Rep 2018 ; 6 : 2050313X18799247
 
9) Choi HY, Jeon U, Lee SW, et al : A case of dysphagia aortica caused by a large thoracic aortic aneurysm. Soonchunhyang Med Sci 2018 ; 24 : 216-219
 
10) Wang ID, Huang HK, Tsai PY, Chang WK : Dysphagia aortica. QJM 2019 ; 112 : 137-138
 
11) Suleman M, Pyuza J, Sadiq A, Lodhia J : Aortic aneurysm : An uncommon cause of dysphagia. SAGE Open Med Case Rep 2022 ; 10 : 2050313X221135602
PubMed
12) Minatoya K, Inoue Y, Sasaki H, et al : Total arch replacement using a 4-branched graft with antegrade cerebral perfusion. J Thorac Cardiovasc Surg 2019 ; 157 : 1370-1378
 
13) Ikeno Y, Yokawa K, Matsueda T, et al : Long-term outcomes of total arch replacement using a 4-branched graft. J Thorac Cardiovasc Surg 2019 ; 157 : 75-85.e3
 
14) 志水秀行, 平原憲道, 本村昇, ほか : 本邦における心臓血管外科手術の現状 : 2017年, 2018年の日本心臓血管外科手術データベースからの報告 4. 胸部大動脈手術. 日心臓血管外会誌 2020 ; 49 : 169-179
 
15) Seike Y, Matsuda H, Fukuda T, et al : Total arch replacement versus debranching thoracic endovascular aortic repair for aortic arch aneurysm : what indicates a high-risk patient for arch repair in octogenarians? Gen Thorac Cardiovasc Surg 2018 ; 66 : 263-269
 
16) Ikeno Y, Yokawa K, Yamanaka K, et al : Total arch replacement in octogenarians and nonagenarians : a single-center 18-year experience. J Thorac Cardiovasc Surg 2020 ; 160 : 346-356.e1
 
17) 伊藤武久, 飯田有輝, 関慎之介, ほか : 心臓外科術患者に対する術前教育の有用性について. 中部リハ誌 2009 ; 4 : 11-13
 
18) Morimoto Y, Matsuo T, Yano Y, et al : Impact of sarcopenia on the progress of cardiac rehabilitation and discharge destination after cardiovascular surgery. J Phys Ther Sci 2021 ; 33 : 213-221
 
19) Rockwood K, Song X, MacKnight C, et al : A global clinical measure of fitness and frailty in elderly people. CMAJ 2005 ; 173 : 489-495
 
20) Kishimoto Y, Yoshikawa Y, Morimoto K, et al : Impact of frailty on early and mid-term outcomes of hybrid aortic arch repair. Surg Today 2022 ; 52 : 1194-1201
 
21) 本多 祐, 向原伸彦, 村上博久, ほか : フレイルが心臓手術後の経過や歩行能力に与える影響. 日心臓血管外会誌 2022 ; 51 : 67-72
 
P.927 掲載の参考文献
1) Connors JM : Thrombophilia Testing and Venous Thrombosis. N Engl J Med 2017 ; 377 : 1177-1187
 
2) Wells PS, Holbrook AM, Crowther NR, Hirsh J : Interactions of warfarin and drugs and food. Ann Inter Med 1994 ; 121 : 676-683
 
3) Hokusai-VTE Investigators ; Buller HR, Decousus H, Grosso MA, et al : Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013 ; 369 : 1406-1415
 
4) Sakata T, Okamoto A, Mannami T, et al : Prevalence of protein S deficiency in the Japanese general population : the Suita Study. J Thromb Haemost 2004 ; 2 : 1012-1013
 
5) Shatzel JJ, O'Donnell M, Olson SR, et al : Venous thrombosis in unusual sites : A practical review for the hematologist. Eur J Haematol 2019 ; 102 : 53-62
 
6) Nakamura M, Miyata T, Ozeki Y, et al : Current venous thromboembolism management and outcomes in Japan. Circ J 2014 ; 78 : 708-717
 
7) Rhee RY, Gloviczki P : Mesenteric venous thrombosis. Surg Clin North Am 1997 ; 77 : 327-338
 
8) Rhee RY, Gloviczki P, Mendonca CT, et al : Mesenteric venous thrombosis : still a lethal disease in the 1990s. J Vasc Surg 1994 ; 20 : 688-697
 
9) Clair DG, Beach JM : Mesenteric Ischemia. N Engl J Med 2016 ; 374 : 959-968
 
10) Okumura K, Komatsu T, Yamashita T, et al : Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. A multicenter study of its status and infuential factors. Circ J 2011 ; 75 : 2087-2094
 
11) Campello E, Spiezia L, Simion C, et al : Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism : A Prospective Cohort Study. J Am Heart Assoc 2020 ; 9 : e018917
PubMed
12) Nagaoki Y, Aikata H, Daijyo K, et al : Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res 2018 ; 48 : 51-58
 
13) Toyoda J, Morioka D, Horii N, et al : Treatment of acute exacerbation of liver-cirrhosis-associated portal vein thrombosis with direct-acting oral anticoagulant, edoxaban, used as an initial treatment in the early postoperative period after abdominal surgery : a case report. J Med Case Rep 2021 ; 15 : 52
PubMed
14) Bikdeli B, Zahedi Tajrishi F, Sadeghipour P, et al : Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants : A Review. JAMA Cardiol 2022 ; 7 : 747-759
 
15) Elsebaie MAT, van Es N, Langston A, et al : Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia : a systematic review and meta-analysis. J Thromb Haemost 2019 ; 17 : 645-656
 

【HEART' s Special】

P.951 掲載の参考文献
1) 日本脳卒中協会 脳卒中ガイドライン委員会・編 : II 脳梗塞・TIA 3 脳梗塞慢性期 3-5 奇異性脳塞栓症 (卵円孔開存が合併した塞栓源不明の脳塞栓症を含む). 脳卒中治療ガイドライン 2021. 東京 : 協和企画 ; 2021. p.109-111
 
2) Mohr JP : Cryptogenic stroke. N Engl J Med 1988 ; 318 : 1197-1198
 
3) Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990 ; 21 : 637-676
 
4) Adams HP Jr, Bendixen BH, Kappelle LJ, et al : Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993 ; 24 : 35-41
 
5) Ay H, Furie KL, Singhal A, et al : An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005 ; 58 : 688-697
 
6) 日本脳卒中協会 脳卒中ガイドライン委員会・編 : II 脳梗塞・TIA 3 脳梗塞慢性期 3-4 塞栓源不明の脳塞栓症 (ESUS, Cryptogenic stroke). 脳卒中治療ガイドライン 2021. 東京 : 協和企画 ; 2021. p.107-108
 
7) Ueno Y, Iguchi Y, Inoue T, et al : Paradoxical brain embolism may not be uncommon-prospective study in acute ischemic stroke. J Neurol 2007 ; 254 : 763-766
 
8) Furlan AJ, Reisman M, Massaro J, et al : Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012 ; 366 : 991-999
 
9) Meier B, Kalesan B, Mattle HP, et al : Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013 ; 368 : 1083-1091
 
10) Carroll JD, Saver JL, Thaler DE, et al : Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013 ; 368 : 1092-1100
 
11) Saver JL, Carroll JD, Thaler DE, et al : Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med 2017 ; 377 : 1022-1032
PubMed
12) Sondergaard L, Kasner SE, Rhodes JF, et al : Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med 2017 ; 377 : 1033-1042
 
13) Mas JL, Derumeaux G, Guillon B, et al : Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med 2017 ; 377 : 1011-1021
 
14) Lee PH, Song JK, Kim JS, et al : Cryptogenic Stroke and High-Risk Patent Foramen Ovale : The DEFENSE-PFO Trial. J Am Coll Cardiol 2018 ; 71 : 2335-2342
 
15) Elgendy AY, Saver JL, Amin Z, et al : Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke. JAMA Neurol 2020 ; 77 : 878-886
 
16) Ando T, Holmes AA, Pahuja M, et al : Meta-Analysis Comparing Patent Foramen Ovale Closure Versus Medical Therapy to Prevent Recurrent Cryptogenic Stroke. Am J Cardiol 2018 ; 121 : 649-655
 
17) Mojadidi MK, Elgendy AY, Elgendy IY, et al : Transcatheter Patent Foramen Ovale Closure After Cryptogenic Stroke : An Updated Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv 2017 ; 10 : 2228-2230
 
18) Vaduganathan M, Qamar A, Gupta A, et al : Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke : Updated Meta-Analysis of Randomized Clinical Trials. Am J Med 2018 ; 131 : 575-577
 
19) Mas JL, Saver JL, Kasner SE, et al : Association of Atrial Septal Aneurysm and Shunt Size With Stroke Recurrence and Benefit From Patent Foramen Ovale Closure. JAMA Neurol 2022 ; 79 : 1175-1179
 
20) Turc G, Calvet D, Guerin P, et al : Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale : Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study. J Am Heart Assoc 2018 ; 7 : e008356
 
21) Toyoda K, Okumura K, Hashimoto Y, et al : Cryptogenic ischemic stroke and embolic stroke of undetermined source : clinical implications and importance for detection of covert atrial fibrillation in Japan. Jpn J Stroke 2016 ; 38 : 77-85
 
22) 北川泰久 : 頭痛診療におけるMissing Link片頭痛と脳梗塞. 臨床神経 2014 ; 54 : 1000-1002
 
23) 片頭痛に対する経皮的卵円孔閉鎖術に関するステートメント委員会 : 片頭痛に対する経皮的卵円孔閉鎖術に関するステートメント. 2017.
 
24) ICD-11. https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/826335789.
 
25) Kent DM, Ruthazer R, Weimar C, et al : An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013 ; 81 : 619-625
 
26) Kent DM, Saver JL, Kasner SE, et al : Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke. JAMA 2021 ; 326 : 2277-2286
 
27) Pristipino C, Bedogni F, Cremonesi A : Patent foramen ovale and cryptogenic stroke. N Engl J Med 2013 ; 369 : 89-90
 
28) Goel SS, Tuzcu EM, Shishehbor MH, et al : Morphology of the patent foramen ovale in asymptomatic versus symptomatic (stroke or transient ischemic attack) patients. Am J Cardiol 2009 ; 103 : 124-129
PubMed
29) Nakayama R, Takaya Y, Akagi T, et al : Identification of High-Risk Patent Foramen Ovale Associated With Cryptogenic Stroke : Development of a Scoring System. J Am Soc Echocardiogr 2019 ; 32 : 811-816
 
30) Rigatelli G, Dell'Avvocata F, Cardaioli P, et al : Permanent right-to-left shunt is the key factor in managing patent foramen ovale. J Am Coll Cardiol 2011 ; 58 : 2257-2261
 
31) Kwon H, Lee PH, Song JK, et al : Patent Foramen Ovale Closure in Old Stroke Patients : A Subgroup Analysis of the DEFENSE-PFO Trial. J Stroke 2021 ; 23 : 289-292
 
32) Takaya Y, Nakayama R, Akagi T, et al : Importance of saline contrast transthoracic echocardiography for evaluating large right-to-left shunt in patent foramen ovale associated with cryptogenic stroke. Int J Cardiovasc Imaging 2022 ; 38 : 515-520
 
33) Pristipino C, Sievert H, D'Ascenzo F, et al : European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J 2019 ; 40 : 3182-3195
 
34) Zetola VF, Lange MC, Scavasine VC, et al : Latin American Consensus Statement for the Use of Contrast-Enhanced Transcranial Ultrasound as a Diagnostic Test for Detection of Right-to-Left Shunt. Cerebrovasc Dis 2019 ; 48 : 99-108
 
35) Kobayashi K, Kimura K, Iguchi Y, et al : Right-to-left-shunt detected by c-TCD using the orbital window in comparison with temporal bone windows. J Neuroimaging 2012 ; 22 : 80-84
 
36) Mitsumura H, Arai A, Sato T, et al : A novel probe attached to the neck can accurately detect a large patent foramen ovale. J Neurol Sci 2018 ; 392 : 122-125
 
37) Komatsu T, Terasawa Y, Arai A, et al : Transcranial color-coded sonography of vertebral artery for diagnosis of right-to-left shunts. J Neurol Sci 2017 ; 376 : 97-101
 
38) Takaya Y, Watanabe N, Ikeda M, et al : Importance of Abdominal Compression Valsalva Maneuver and Microbubble Grading in Contrast Transthoracic Echocardiography for Detecting Patent Foramen Ovale. J Am Soc Echocardiogr 2020 ; 33 : 201-206
 
39) Pearson AC, Nagelhout D, Castello R, et al : Atrial septal aneurysm and stroke : a transesophageal echocardiographic study. J Am Coll Cardiol 1991 ; 18 : 1223-1229
 
40) Wessler BS, Thaler DE, Ruthazer R, et al : Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale : analysis of putative high-risk features from the risk of paradoxical embolism database. Circ Cardiovasc Imaging 2014 ; 7 : 125-131
 
41) Hahn RT, Abraham T, Adams MS, et al : Guidelines for performing a comprehensive transesophageal echocardiographic examination : recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr 2013 ; 26 : 921-964
 
42) Vale TA, Newton JD, Orchard E, et al : Prominence of the Eustachian valve in paradoxical embolism. Eur J Echocardiogr 2011 ; 12 : 33-36
 
43) Homma S, Sacco RL, Di Tullio MR, et al : Atrial anatomy in non-cardioembolic stroke patients : effect of medical therapy. J Am Coll Cardiol 2003 ; 42 : 1066-1072
 

書評

最近チェックした商品履歴

Loading...